Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Operations (2018 - 2025)

X4 Pharmaceuticals' Cash from Operations history spans 8 years, with the latest figure at 15518000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 52.97% year-over-year to 15518000.0; the TTM value through Dec 2025 reached 85618000.0, up 47.96%, while the annual FY2025 figure was 85618000.0, 34.59% up from the prior year.
  • Cash from Operations reached 15518000.0 in Q4 2025 per XFOR's latest filing, up from 27831000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 12400000.0 in Q1 2025 to a low of 68800000.0 in Q3 2023.
  • Average Cash from Operations over 5 years is 28455400.0, with a median of 23370500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 256.37% in 2023, then skyrocketed 63.09% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 19053000.0 in 2021, then decreased by 0.21% to 19093000.0 in 2022, then plummeted by 45.33% to 27747000.0 in 2023, then dropped by 18.91% to 32995000.0 in 2024, then skyrocketed by 52.97% to 15518000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Cash from Operations are 15518000.0 (Q4 2025), 27831000.0 (Q3 2025), and 29869000.0 (Q2 2025).